Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 76-IMMUNOBILADJ
2023-503807-27-00Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in biliary cancer, hilar cholangiocarcinoma (HC), distal cholangiocarcinoma (dCCA) and 2 more comparing Capecitabine alone with Capecitabine plus durvalumab (2 arms). Primary endpoint: Disease-free survival rate at 18 months. Started Jul 2023; status: completed.
02
Drugs
durvalumabcapecitabine
03
Conditions
biliary cancerhilar cholangiocarcinoma (HC)distal cholangiocarcinoma (dCCA)intrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on 2023-503807-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503807-27-00.